ВАККА Джозеф П. (US),КОБЕРН Крэйг А. (US),ОЛСЕН Дэвид Б. (US),КОЗЛОВСКИ Джозеф А. (US),РОЗЕНБЛЮМ Стюарт Б. (US)
申请号：
RU2013119607/15
公开号：
RU2013119607A
申请日:
2011.09.28
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A pharmaceutical composition comprising: (i) a pharmaceutically acceptable carrier (Ii) a compound selected from the following table: or a pharmaceutically acceptable salt thereof and (iii) the first additional therapeutic agent is selected from compounds of F1-F28 and pharmaceutically acceptable salts thereof, wherein the amounts of the compounds of Table 1 and the first additional therapeutic agent are selected so that they are jointly effective for treating HCV infection in patsienta.2. A pharmaceutical composition according to claim 1, wherein the first additional therapeutic agent is selected from: .3. A pharmaceutical composition according to claim 2, wherein the first additional therapeutic agent is soboy.4. A pharmaceutical composition according to claim 1 or 2, further comprising a second additional therapeutic agent is not a compound of Table 1 of Claim 1, or a pharmaceutically acceptable salt thereof, wherein this second additional therapeutic agent selected from HCV antiviral agent, an immunomodulator, and anti-infective agents. 5. A pharmaceutical composition according to claim 4, wherein the second additional therapeutic agent selected from a HCV protease inhibitor, interferon and polimerazy.6 HCV inhibitor. A pharmaceutical composition according to claim 5, wherein the second additional therapeutic agent is a pegylated interferon alfa.7. A pharmaceutical composition according to claim 6, further comprising ribavirin.8. A method of treating a patient infected with HCV, comprising administering to the patient: (i) a compound selected from Table 1, claim 1, or a pharmaceutically acceptable salt thereof and (ii) the first additional therapeutic1. Фармацевтическая композиция, включающая: (i) фармацевтически приемлемый носитель (ii) соединение, выбранное из приведенной ниже таблицы:или его фармацевтически приемлемую соль и (iii) первое дополнительное терапевтическое средство, которое выбрано из соединений F1-F28 и их фармацевтически приемлемых солей, где
